{
  "meta": {
    "title": "Cancer_Biology_-_1_Growth_Factors_Transcription_Factors",
    "url": "https://brainandscalpel.vercel.app/cancer-biology-1-growth-factors-transcription-factors-6519ef40.html",
    "scrapedAt": "2025-11-29T18:24:56.947Z"
  },
  "questions": [
    {
      "id": 19749,
      "choices": [
        {
          "id": 78957,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Proto-oncogenes causes cancer by gain of function mutations, while tumor suppressor genes cause cancer due to loss of function mutations.</span></span></p>"
        },
        {
          "id": 78958,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Proto-oncogenes are typically inactivated in cancer, while tumor suppressor genes are overactivated.</span></span></p>"
        },
        {
          "id": 78959,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Proto-oncogenes are exclusively found in malignant tumors, while tumor suppressor genes are found in benign tumors.</span></span></p>"
        },
        {
          "id": 78960,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Proto-oncogenes encode for growth factors, while tumor suppressor genes encode for growth factor receptors.</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the context of cancer development, which of the following statements best differentiates proto-oncogenes from tumor suppressor genes?</span></span></p>",
      "unique_key": "Q1570683",
      "question_audio": null,
      "question_video": null,
      "map_id": 19582,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Proto-oncogenes cause cancer by gain of function mutations, while tumor suppressor genes cause cancer due to loss of function mutations.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Proto-oncogenes are normal genes that, when mutated or overexpressed, become oncogenes that can contribute to cancer development. These mutations often result in a gain of function, leading to increased cell growth and proliferation. Examples include the RAS and MYC genes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tumor suppressor genes, on the other hand, normally act to regulate cell growth and prevent uncontrolled cell division. When these genes are inactivated or mutated, their protective functions are lost, leading to the development of cancer. This is typically due to loss of function mutations. Examples include the TP53 and RB1 genes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B</span></strong><span style=\"font-size:12.0pt\">. Proto-oncogenes are not typically inactivated in cancer; they are activated or overexpressed. Tumor suppressor genes are often inactivated or under expressed in cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> Both proto-oncogenes and tumor suppressor genes can be involved in both malignant and benign tumors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> Proto-oncogenes and tumor suppressor genes can encode a variety of proteins, not limited to growth factors and growth factor receptors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Proto-oncogenes and tumor suppressor genes are two key classes of genes involved in cancer development. Proto-oncogenes promote cell growth and proliferation and can lead to cancer when mutated to gain function. Tumor suppressor genes normally inhibit cell growth, and their inactivation or loss of function can contribute to cancer development.</span></span></p>",
      "correct_choice_id": 78957,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19750,
      "choices": [
        {
          "id": 78961,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">JAK2 V617F </span></span></p>"
        },
        {
          "id": 78962,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">EGFR exon 20 insertion </span></span></p>"
        },
        {
          "id": 78963,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BRAF V600E </span></span></p>"
        },
        {
          "id": 78964,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">5q deletion</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following mutations is MOST likely to be associated with a myeloproliferative neoplasm?</span></span></p>",
      "unique_key": "Q7312271",
      "question_audio": null,
      "question_video": null,
      "map_id": 19583,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) JAK2 V617F</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">JAK2 V617F is a gain-of-function mutation in the JAK2 gene, a tyrosine kinase, frequently found in myeloproliferative neoplasms like polycythemia vera and essential thrombocythemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. EGFR exon 20 insertion:</span></strong><span style=\"font-size:12.0pt\"> This mutation is commonly found in non-small cell lung cancer (NSCLC) and is associated with resistance to certain targeted therapies. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. BRAF V600E:</span></strong><span style=\"font-size:12.0pt\"> This mutation is commonly found in melanoma and some other solid tumors. It is not typically associated with myeloproliferative neoplasms. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. 5q deletion:</span></strong><span style=\"font-size:12.0pt\"> This is a chromosomal deletion frequently found in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), but not as commonly in myeloproliferative neoplasms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">JAK2 V617F is a key driver mutation in several myeloproliferative neoplasms and a target for therapies like ruxolitinib.</span></span></p>",
      "correct_choice_id": 78961,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19751,
      "choices": [
        {
          "id": 78965,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trinucleotide repeat expansion in the HTT gene </span></span></p>"
        },
        {
          "id": 78966,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Deletion of phenylalanine at position 508 of the CFTR gene</span></span></p>"
        },
        {
          "id": 78967,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Point mutation resulting in a glutamate to valine substitution in the &beta;-globin gene</span></span></p>"
        },
        {
          "id": 78968,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Translocation between chromosomes 9 and 22 (t(9;22))</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 15-year-old African American boy presents with acute onset of severe bone pain in his lower extremities. His history includes similar episodes, often precipitated by dehydration or stress. Lab results reveal anemia, elevated reticulocyte count, and indirect hyperbilirubinemia. A peripheral blood smear demonstrates sickled erythrocytes. Which genetic alteration is MOST likely responsible for this patient&#39;s condition?</span></span></p>",
      "unique_key": "Q6564258",
      "question_audio": null,
      "question_video": null,
      "map_id": 19584,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Point mutation resulting in a glutamate to valine substitution in the &beta;-globin gene</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation and laboratory findings are classic for a sickle cell crisis in a patient with sickle cell disease (SCD). SCD arises from a single point mutation in the &beta;-globin gene (HBB), specifically a substitution of glutamic acid (a negatively charged amino acid) with valine (a hydrophobic amino acid) at position 6. This alteration changes the hemoglobin&#39;s structure, causing it to polymerize under low oxygen conditions, leading to sickled red blood cells and subsequent vaso-occlusion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Trinucleotide repeat expansion in the HTT gene:</span></strong><span style=\"font-size:12.0pt\"> This mutation is associated with Huntington&#39;s disease, a neurodegenerative disorder.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Deletion of phenylalanine at position 508 of the CFTR gene:</span></strong><span style=\"font-size:12.0pt\"> This is the most common mutation in cystic fibrosis, causing defective chloride ion transport.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Translocation between chromosomes 9 and 22 (t(9;22)):</span></strong><span style=\"font-size:12.0pt\"> This is the Philadelphia chromosome, a hallmark of chronic myeloid leukemia (CML).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sickle cell disease is a monogenic disorder caused by a specific point mutation in the &beta;-globin gene. Understanding the molecular basis of SCD is crucial for diagnosis, management, and potential future gene therapies.</span></span></p>",
      "correct_choice_id": 78967,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19752,
      "choices": [
        {
          "id": 78969,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Point mutation in the p53 gene </span></span></p>"
        },
        {
          "id": 78970,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Deletion of the RB1 gene </span></span></p>"
        },
        {
          "id": 78971,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypermethylation of the promoter region of a tumor suppressor gene </span></span></p>"
        },
        {
          "id": 78972,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Translocation between chromosomes 9 and 22</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is an example of an epigenetic change that can contribute to cancer development?</span></span></span></p>",
      "unique_key": "Q3588472",
      "question_audio": null,
      "question_video": null,
      "map_id": 19585,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Hypermethylation of the promoter region of a tumor suppressor gene</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Epigenetic changes, such as DNA methylation, can alter gene expression without changing the DNA sequence itself. Hypermethylation of tumor suppressor gene promoters can silence their expression, leading to cancer development. The other options represent genetic mutations, not epigenetic changes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><span style=\"font-size:12.0pt\">:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Point mutation in the p53 gene:</span></strong><span style=\"font-size:12.0pt\"> This is a genetic alteration where a single nucleotide in the DNA sequence of the p53 gene is changed. This can lead to the production of a dysfunctional p53 protein, which is a tumor suppressor. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Deletion of the RB1 gene:</span></strong><span style=\"font-size:12.0pt\"> This is also a genetic alteration where a portion of the RB1 gene, another tumor suppressor, is removed. The absence of the RB1 protein can contribute to uncontrolled cell growth. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Translocation between chromosomes 9 and 22:</span></strong><span style=\"font-size:12.0pt\"> This is a chromosomal rearrangement where a piece of chromosome 9 is transferred to chromosome 22, and vice versa. This translocation creates a new fusion gene, often the BCR-ABL gene, which drives the development of chronic myeloid leukemia (CML).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Epigenetic modifications, like DNA methylation, play a significant role in carcinogenesis.</span></span></p>",
      "correct_choice_id": 78971,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19753,
      "choices": [
        {
          "id": 78973,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">E2 </span></span></p>"
        },
        {
          "id": 78974,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">E4 </span></span></p>"
        },
        {
          "id": 78975,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">E6</span></span></p>"
        },
        {
          "id": 78976,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">E8</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following HPV genes is MOST directly implicated in the development of cervical cancer?</span></span></p>",
      "unique_key": "Q4310856",
      "question_audio": null,
      "question_video": null,
      "map_id": 19586,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><strong>C) E6</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">E6 and E7 are the primary oncogenes of HPV. E6 inactivates p53, a tumor suppressor protein, while E7 inhibits the retinoblastoma (Rb) protein, both of which are critical for cell cycle regulation. &nbsp;</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. E2:</span></strong><span style=\"font-size:12.0pt\"> E2 is involved in viral replication and gene expression regulation. While important for the HPV lifecycle, it&#39;s not directly implicated in cellular transformation and cancer development.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. E4:</span></strong><span style=\"font-size:12.0pt\"> E4 plays a role in viral release and assembly. It&#39;s not considered a major oncogenic protein in the context of cervical cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. E8:</span></strong><span style=\"font-size:12.0pt\"> There is no E8 gene in the HPV genome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The E6 and E7 proteins are the primary oncoproteins of HPV that drive the development of cervical cancer by interfering with critical cellular pathways that regulate cell growth and survival.</span></span></p>",
      "correct_choice_id": 78975,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19754,
      "choices": [
        {
          "id": 78977,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibition of BCR-ABL tyrosine kinase</span></span></p>"
        },
        {
          "id": 78978,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibition of mutant IDH2 enzyme</span></span></p>"
        },
        {
          "id": 78979,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stimulation of the immune system to attack leukemia cells</span></span></p>"
        },
        {
          "id": 78980,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Induction of differentiation of leukemia cells</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 58-year-old man with a history of refractory acute myeloid leukemia (AML) presents to the oncology clinic for a follow-up visit. He was recently started on enasidenib after genetic testing revealed a specific mutation in his leukemia cells. The patient has noticed a decrease in fatigue and an improvement in his overall well-being since starting the treatment. The oncologist explains the mechanism of action of the medication, which targets the leukemia cells. Which of the following best describes the mechanism of action of enasidenib?</span></span></p>",
      "unique_key": "Q7228696",
      "question_audio": null,
      "question_video": null,
      "map_id": 19587,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Inhibition of mutant IDH2 enzyme</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Enasidenib is a targeted therapy that inhibits the mutant isocitrate dehydrogenase 2 (IDH2) enzyme, which is found in some patients with acute myeloid leukemia (AML). The IDH2 mutation leads to the production of an oncometabolite called 2-hydroxyglutarate (2-HG), which contributes to the development and progression of AML by altering the epigenetic regulation of gene expression and blocking the differentiation of myeloid cells. By inhibiting the mutant IDH2 enzyme, enasidenib reduces the levels of 2-HG, thereby promoting the differentiation of myeloid cells and leading to clinical improvement in patients with IDH2-mutant AML.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><span style=\"font-size:12.0pt\">:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Inhibition of BCR-ABL tyrosine kinase</span></strong><span style=\"font-size:12.0pt\">: This is the mechanism of action of drugs like imatinib, which are used to treat chronic myeloid leukemia (CML), not AML.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Stimulation of the immune system to attack leukemia cells</span></strong><span style=\"font-size:12.0pt\">: This describes the mechanism of action of immunotherapies, such as CAR T-cell therapy, rather than enasidenib.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Induction of differentiation of leukemia cells</span></strong><span style=\"font-size:12.0pt\">: While enasidenib does lead to differentiation of leukemia cells, it is more specific to say that it inhibits the mutant IDH2 enzyme, which is the direct target of the drug.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><span style=\"font-size:12.0pt\">:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Enasidenib is a targeted therapy used to treat patients with acute myeloid leukemia (AML) who have a specific mutation in the IDH2 enzyme. It works by inhibiting the mutant enzyme, leading to a reduction in the oncometabolite 2-HG and promoting the differentiation of myeloid cells.</span></span></p>",
      "correct_choice_id": 78978,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}